Plus Therapeutics’ Promising Phase 1 Results for Rhenium-186Re-Obisbemeda in Glioblastoma: A New Hope, Published in Nature Communications

Rhenium (186 Re) Obisbemeda: A Promising Treatment for Glioblastoma In a recent development, Plus Therapeutics, Inc. announced the publication of results from a Phase 1 clinical trial of Rhenium (186 Re) Obisbemeda in the prestigious medical journal, Nature Communications. This trial focused on the treatment of recurrent glioblastoma (GBM), a type of brain cancer known…

Read More